Currently, LLDT-8 is being investigated as a low-toxicity immunosuppressive agent in Phase I clinical trials for the treatment of RA in China 148, and the results show that LLDT-8 can inhibit the production of MMP-13 and increase the expression of OPG/RANKL through the OPG/RANK/RANK ligand signaling pathway to weaken collagen-induced arthritis (CIA). This evidence concerns the gene TNFRSF11A and rheumatoid arthritis.